Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 3770854
Author(s) Vizeli, Patrick; Schmid, Yasmin; Prestin, Katharina; Meyer Zu Schwabedissen, Henriette E.; Liechti, Matthias E.
Author(s) at UniBasel Meyer zu Schwabedissen, Henriette
Liechti, Matthias Emanuel
Year 2017
Title Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects
Journal European Neuropsychopharmacology
Volume 27
Number 3
Pages / Article-Number 232-238
Mesh terms 3,4-Methylenedioxyamphetamine, metabolism; Adolescent; Adult; Cross-Sectional Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System, genetics; Double-Blind Method; Female; Genotype; Hallucinogens, pharmacology; Healthy Volunteers; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine, pharmacology; Pharmacogenetics; Polymorphism, Genetic; Time Factors; Young Adult
Abstract In vitro studies showed that CYP2C19, CYP2B6, and CYP1A2 contribute to the metabolism of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) to 3,4-methylenedioxyamphetamine (MDA). However, the role of genetic polymorphisms in CYP2C19, CYP2B6, and CYP1A2 in the metabolism of MDMA in humans is unknown. The effects of genetic variants in these CYP enzymes on the pharmacokinetics and pharmacodynamics of MDMA were characterized in 139 healthy subjects (69 male, 70 female) in a pooled analysis of eight double-blind, placebo-controlled studies. MDMA-MDA conversion was positively associated with genotypes known to convey higher CYP2C19 or CYP2B6 activities. Additionally, CYP2C19 poor metabolizers showed greater cardiovascular responses to MDMA compared with other CYP2C19 genotypes. Furthermore, the maximum concentration of MDA was higher in tobacco smokers that harbored the inducible CYP1A2 rs762551 A/A genotype compared with the non-inducible C-allele carriers. The findings indicate that CYP2C19, CYP2B6, and CYP1A2 contribute to the metabolism of MDMA to MDA in humans. Additionally, genetic polymorphisms in CYP2C19 may moderate the cardiovascular toxicity of MDMA.
Publisher Elsevier
ISSN/ISBN 0924-977X ; 1873-7862
edoc-URL http://edoc.unibas.ch/56146/
Full Text on edoc Available
Digital Object Identifier DOI 10.1016/j.euroneuro.2017.01.008
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/28117133
ISI-Number WOS:000396971100003
Document type (ISI) Journal Article, Randomized Controlled Trial
 
   

MCSS v5.8 PRO. 0.354 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
27/05/2024